European Archives - Page 507 of 1104 - European Medical Journal

Genome Editing and CAR-T Cell Therapy

Recent efforts to incorporate genome editing into CAR T cell therapy offers novel opportunities for treatment of haematologic malignancies…

Can 3D-Printed Blood Plasma Improve Wound Healing?

3D-printed PRP implant demonstrated its ability to improve the speed of wound healing through enabling increasingly efficient vascularisation

Second Untreated Patient with HIV Achieves Sterilising Cure

Team have now reported a second patient with no intact HIV viral sequences found in the analysis of more than 1.19 billion blood cells

The Alternative: Herbal Medicine

This week, Jonathan continues his series on alternative medicine by taking us back in time to the roots of medicine through herbal remedies.

Factor XI Inhibition: The Holy Grail of Haemostasis-Sparing Anticoagulation

Ajay Kakkar opened this virtual meeting by discussing the history of the treatment and prevention of thrombosis…

EMJ 6.4 2021

Email subject line: Homozygous familial hypercholesterolaemia and biomarkers for COVID-19 in EMJ 6.4Introduction…

Evra (Norelgestromin and Ethinyl Oestradiol) and Contraceptive Options Available to Females Today

Increased contraceptive choice is a pivotal shift in modern contraception that has improved the autonomy of females and may help to better match contraception to their individual and cultural identities.

Neurofibromatosis Type 1: Burden of Disease in Patients with Plexiform Neurofibromas

NF1 is an autosomal dominant disorder, arising from a mutation in the gene that encodes neurofibromin. It is a tumour-predisposing…

Management and Multi-specialty Approach in the Evolving Treatment Landscape of Neurofibromatosis Type 1 Plexiform Neurofibromas

Neurofibromatosis Type 1 (NF1) is a rare disease, occurring in approximately 1 in 3,000 people. Among the numerous manifestations…

Aficamten: A New Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

REDWOOD-HCM was a multicentre, randomised, placebo-controlled, double-blind, dose-finding clinical trial of aficamten in patients with symptomatic oHCM on background medical therapy.